1. Harrow, Inc. focuses on ophthalmology products with Iheezo, Vevye, and Triesence, but faces debateable clinical differentiation. 2. The company reported a record $48.9 million in Q2 revenue, with a 46% year-over-year increase, but continues to experience net losses. 3. Harrow's current ratio indicates strong short-term financial health, but a significant debt due in 2026 could impact its cash runway.